Figure legend for supplemental figure

Infrared images at 4 and 8 weeks after the start of intravitreal brolucizumab (IVBr) treatment showed a suspicious shadow or dark area (red arrow head) and the vertical scan OCT images showed some vitreous haze and vitreous noise. (red arrow) However, vitreous haze is seen over the fovea where there is no shadow on the infrared image and no vitreous noise on the horizontal scan image. Furthermore, there is no change in the luminance of the retinal image underlying the noise.

the infrared image at 16weeks showed an obvious smoke-like shadow (orange arrow head) and the OCT image shows obvious vitreous noise in both the horizontal and vertical scans. In the area where the darkest shadow is seen in the infrared image, the luminance of the retinal image underlying the vitreous noise decreases (orange arrow), indicating that there is something in the vitreous that interferes with the OCT scan